Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 13 (20), 1755-1766

A Review of Binimetinib for the Treatment of Mutant Cutaneous Melanoma

Affiliations
Review

A Review of Binimetinib for the Treatment of Mutant Cutaneous Melanoma

Peter Koelblinger et al. Future Oncol.

Abstract

Although significant progress has been made in the treatment of unresectable or metastatic melanoma, at least half of all advanced melanoma patients eventually progress and pass away due to their disease. In particular, patients with NRAS-mutated melanoma still face limited therapeutic options, with immunotherapy being the current treatment type of choice. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. The results of a recent Phase III trial rendered binimetinib the first targeted therapy agent to significantly improve progression-free survival in NRAS-mutated melanoma. This review will summarize the development and clinical data of binimetinib in melanoma in general and also explore the potential future role of this substance as single agent or combination therapy.

Keywords: BRAF-mutated melanoma; MAPK pathway; NRAS mutations; binimetinib.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

MeSH terms

Supplementary concepts

LinkOut - more resources

Feedback